Resverlogix Corp.

Events/Webcasts

Webcasts & Presentations

Periocically Resverlogix will webcast from selected conferences/events. Active links will be posted here.

October 17, 2017: BIO Investor Forum 2017: PDF Presentation

September 26, 2017: BioPharm America 2017: PDF Presentation

June 19, 2017: BIO International Convention: PDF Presentation

June 5, 2017: European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress Symposium: "Manging CKD, Diabetes & CVD: Is epigenetics a new way forward?"
Symposium presentations may be viewed HERE

May 1, 2017: Bloom Burton & Co. Healthcare Investor Conference: PDF Presentation

March 21, 2017: BIO-Europe Spring: PDF Presentation

March 8, 2017: Cowen and Company 37th Annual Health Care Conference: PDF Presentation

February 14, 2017: BIO CEO & Investor Conference: PDF Presentation

February 2, 2017: Keystone Symposia: Epigenetics and Human Disease: Progress from Mechanisms to Therapeutics, Seattle, WA. PDF of Abstract.

January 9, 2017: 9th Annual Biotech Showcase Conference:  PDF Presentation

December 15, 2016: Resverlogix Annual General Meeting and Corporate Update: Link to webcast PDF Presentation

2016 Research & Development Update for apabetalone (RVX-208) in New York City. Webcast can be accessed by clicking HERE

Full Presentation
Research & Development Update

Individual Presentations
Unmet Need in Diabetes and CVD & RVX MACE Analysis - Prof. Kausik Ray
Apabetalone: Current Research and Development - Ewelina Kulikowski, BSc, PhD
BETonMACE Clinical Update - Michael Sweeney, MD
Unmet Need in CKD & RVX MACE Analysis - Kamyar Kalantar-Zadeh, MD, PhD
Market Opportunity and Concluding Remarks - Donald J. McCaffrey, President & CEO

September 14th, 2016, Resverlogix presented a poster at the 52nd European Association for the Study of Diabetes (EASD) Annual Meeting. The eVideo presentation can be accessed here: https://youtu.be/dNtA5kPwpZg

August 28th, 2016, Resverlogix supported a PACE-CME educational symposium at the ESC Congress 2016, titled: A Novel Approach for High CV Risk Patients with Diabetes: The Potential of Epigenetics. Expert presenters included: Prof. Kausik Ray, Imperial College, London, UK, Dr. Jorge Plutzky, Brigham and Woman’s Hospital, Harvard Medical School, Boston, MA, and Prof. John Kastelein, Academic Medical Center, Amsterdam, Netherlands. Meeting Highlights, Videos and Slides of the symposium can be accessed HERE.

Current Events

Resverlogix will be attending several key industry conferences. Website will be udated as presentation opportunities become available. Please note: not all events offer a presentation opportunity and this list is subject to change.

Oct. 17-18: BIO Investor Forum 2017, San Francisco, CA.
      Presentation Date: Tuesday, October 17
      Presentation Time: 9:00am PT

Resverlogix in the Media

March 29, 2016: CTV news filmed on location the RVX lab featuring the Sanofi Biogenius competition

January 20, 2016: Resverlogix featured in the Life Sciences Report

September 2015: At the 2015 Rodman & Renshaw healthcase conference, Don McCaffrey had a video interview with Stock News Now (SNN).

August 26, 2015: Resverlogix featured in the Life Sciences Report: Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey

June 25, 2015: Resverlogix’s Dr. Ewelina Kulikowski has written and published an article for the summer 2015 issue of the European Biopharmaceutical Review (EBR) titled, “New Direction.”

April 22, 2015: Donald McCaffrey, President & CEO on BNN’s Business Day
 

April 27, 2015: BioCentury: Hepalink gains rights to Resverlogix’s RVX-208 in China

April 28, 2015: BioWorld Today: Phase III Starting Soon. Resverlogix getting specific: With potential $400M BET, Hepalink licensing accord, by Randy Osborne. 

April 28, 2015: GEN News Highlights: Hepalink Buys China-Area Rights to Resverlogix's CV Candidate for Up-to-$441.5M.

To arrange a media interview, please contact Investor Relations at ir@resverlogix.com.